Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Sep;24(3):393–396. doi: 10.1111/j.1365-2125.1987.tb03187.x

Propranolol disposition in patients with hepatosplenic schistosomiasis.

M M Homeida 1, H M Ali 1, B M Arbab 1, D W Harron 1
PMCID: PMC1386264  PMID: 3663453

Abstract

Eight Sudanese patients with hepatosplenic schistosomiasis and seven Sudanese controls were administered a single oral dose of long acting (LA), propranolol 160 mg; blood propranolol levels were measured at regular intervals for 12 h using g.l.c. In patients with hepatosplenic schistosomiasis, propranolol blood concentrations were greater (P less than 0.05) at all time intervals, Cmax 63.5 (29-143) ng ml-1 (median and range) than controls Cmax 23 (12-37) ng ml-1. Median AUC0-12 was also greater (P less than 0.05) (533 and 218 ng ml-1 h respectively), tmax were not significantly different. In patients and controls prior to treatment, standing heart rate (77.5 (60-110), 72 (68-74) beats min-1) systolic (120 (105-150), 110 (100-120) mm Hg) and diastolic blood pressure (75 (60-90), 70 (60-80) mm Hg) were not significantly different. However following propranolol administration a reduction (P less than 0.05) occurred in both systolic (median 20 mm Hg) and diastolic (median 12.5 mm Hg) blood pressure in the patients compared with controls. Heart rate was reduced by a median of 10 beats min-1 in both groups. These observations indicate that propranolol bioavailability in patients with hepatosplenic schistosomiasis is increased possibly due to reduced presystemic extraction.

Full text

PDF
393

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Branch R. A., James J., Read A. E. A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br J Clin Pharmacol. 1976 Apr;3(2):243–249. doi: 10.1111/j.1365-2125.1976.tb00599.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brant P. C., Prata A. Altered drug metabolism in hepatosplenic schistosomiasis. Rev Inst Med Trop Sao Paulo. 1979 Sep-Oct;21(5):254–259. [PubMed] [Google Scholar]
  3. Daneshmend T. K., Homeida M. A. Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan. J Antimicrob Chemother. 1987 Jan;19(1):87–93. doi: 10.1093/jac/19.1.87. [DOI] [PubMed] [Google Scholar]
  4. Daneshmend T. K., Homeida M., Kaye C. M., Elamin A. A., Roberts C. J. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. Gut. 1982 Oct;23(10):807–813. doi: 10.1136/gut.23.10.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dunn M. A., Kamel R. Hepatic schistosomiasis. Hepatology. 1981 Nov-Dec;1(6):653–661. doi: 10.1002/hep.1840010615. [DOI] [PubMed] [Google Scholar]
  6. Hayes P., Bouchier I. A. Drug therapy of portal hypertension and oesophageal varices. Br J Hosp Med. 1984 Jul;32(1):39–42. [PubMed] [Google Scholar]
  7. Homeida M., Salih S. Y., Branch R. A. Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine. Gut. 1978 Sep;19(9):808–811. doi: 10.1136/gut.19.9.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kates R. E. Calcium antagonists. Pharmacokinetic properties. Drugs. 1983 Feb;25(2):113–124. doi: 10.2165/00003495-198325020-00002. [DOI] [PubMed] [Google Scholar]
  9. Lebrec D., Nouel O., Corbic M., Benhamou J. P. Propranolol--a medical treatment for portal hypertension? Lancet. 1980 Jul 26;2(8187):180–182. doi: 10.1016/s0140-6736(80)90063-x. [DOI] [PubMed] [Google Scholar]
  10. Lebrec D., Poynard T., Hillon P., Benhamou J. P. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med. 1981 Dec 3;305(23):1371–1374. doi: 10.1056/NEJM198112033052302. [DOI] [PubMed] [Google Scholar]
  11. Routledge P. A., Shand D. G. Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979 Mar-Apr;4(2):73–90. doi: 10.2165/00003088-197904020-00001. [DOI] [PubMed] [Google Scholar]
  12. Shand D. G., Rangno R. E. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology. 1972;7(3):159–168. doi: 10.1159/000136285. [DOI] [PubMed] [Google Scholar]
  13. Williams R. L., Mamelok R. D. Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet. 1980 Nov-Dec;5(6):528–547. doi: 10.2165/00003088-198005060-00002. [DOI] [PubMed] [Google Scholar]
  14. Wood A. J., Kornhauser D. M., Wilkinson G. R., Shand D. G., Branch R. A. The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet. 1978 Nov-Dec;3(6):478–487. doi: 10.2165/00003088-197803060-00005. [DOI] [PubMed] [Google Scholar]
  15. el-Raghy I., Back D. J., Osman F., Nafeh M. A., Orme M. L. The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis. Br J Clin Pharmacol. 1985 Oct;20(4):313–316. doi: 10.1111/j.1365-2125.1985.tb05069.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES